Your browser is no longer supported. Please, upgrade your browser.
AVEO Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.71 Insider Own0.12% Shs Outstand26.29M Perf Week-8.79%
Market Cap227.81M Forward P/E- EPS next Y-0.17 Insider Trans0.00% Shs Float23.95M Perf Month-8.27%
Income-35.60M PEG- EPS next Q-0.55 Inst Own32.90% Short Float6.61% Perf Quarter-29.46%
Sales6.00M P/S37.97 EPS this Y-372.30% Inst Trans0.33% Short Ratio0.60 Perf Half Y11.05%
Book/sh1.34 P/B4.80 EPS next Y91.70% ROA-56.00% Target Price- Perf Year-21.59%
Cash/sh1.74 P/C3.69 EPS next 5Y- ROE-109.00% 52W Range4.07 - 18.24 Perf YTD11.44%
Dividend- P/FCF- EPS past 5Y9.20% ROI-79.20% 52W High-64.75% Beta1.22
Dividend %- Quick Ratio3.90 Sales past 5Y-20.60% Gross Margin- 52W Low57.99% ATR0.41
Employees49 Current Ratio3.90 Sales Q/Q12.50% Oper. Margin- RSI (14)39.37 Volatility7.06% 5.87%
OptionableYes Debt/Eq0.39 EPS Q/Q-57.80% Profit Margin- Rel Volume0.30 Prev Close6.63
ShortableYes LT Debt/Eq0.36 EarningsMay 10 AMC Payout- Avg Volume2.65M Price6.43
Recom1.20 SMA20-4.85% SMA50-20.24% SMA200-2.28% Volume803,438 Change-3.02%
Nov-09-20Initiated Stifel Buy $9
Aug-13-20Initiated SVB Leerink Outperform $7
Sep-11-19Upgrade H.C. Wainwright Neutral → Buy $1.75
Feb-04-19Downgrade B. Riley FBR Buy → Neutral $5 → $1
Feb-01-19Downgrade H.C. Wainwright Buy → Neutral $1
Jan-04-19Initiated Robert W. Baird Outperform
Nov-13-17Initiated B. Riley FBR, Inc. Buy $5
May-19-16Initiated Piper Jaffray Overweight $1.70
Mar-30-16Initiated FBR Capital Outperform $3
Mar-09-15Upgrade RBC Capital Mkts Underperform → Sector Perform $2 → $3
Dec-16-13Downgrade RBC Capital Mkts Sector Perform → Underperform $5 → $2
May-03-13Upgrade Stifel Sell → Hold
May-03-13Downgrade RBC Capital Mkts Outperform → Sector Perform $15 → $6
May-03-13Downgrade Canaccord Genuity Buy → Hold $2
Dec-21-12Reiterated RBC Capital Mkts Outperform $18 → $15
Nov-14-12Initiated Stifel Nicolaus Sell
May-04-12Reiterated RBC Capital Mkts Outperform $24 → $19
May-13-11Upgrade MP Advisors Underperform → Market Perform $11 → $20
Nov-30-10Initiated RBC Capital Mkts Outperform $24
Nov-29-10Initiated MP Advisors Underperform $8
May-03-21 07:00AM  
Apr-22-21 12:33PM  
Apr-16-21 07:00AM  
Mar-29-21 07:00AM  
Mar-26-21 04:01PM  
Mar-23-21 10:32PM  
Mar-22-21 04:01PM  
Mar-19-21 08:21AM  
Mar-16-21 05:35PM  
Mar-15-21 10:41AM  
Mar-12-21 12:58PM  
Mar-11-21 04:05PM  
Mar-10-21 05:52PM  
Mar-08-21 12:30PM  
Mar-02-21 07:00AM  
Feb-18-21 07:00AM  
Feb-17-21 04:15PM  
Feb-11-21 07:00AM  
Jan-20-21 07:00AM  
Jan-15-21 08:00AM  
Jan-07-21 07:00AM  
Jan-06-21 07:00AM  
Jan-05-21 07:00AM  
Dec-07-20 08:14PM  
Nov-10-20 07:00AM  
Nov-09-20 06:35PM  
Nov-05-20 07:00AM  
Nov-03-20 12:30PM  
Oct-19-20 07:00AM  
Oct-16-20 09:58AM  
Oct-14-20 10:03AM  
Oct-13-20 08:36AM  
Oct-09-20 12:30PM  
Oct-08-20 11:37AM  
Oct-07-20 10:49AM  
Oct-06-20 08:54AM  
Sep-22-20 08:34AM  
Sep-15-20 04:05PM  
Sep-14-20 08:07AM  
Sep-09-20 12:42PM  
Sep-08-20 01:11PM  
Sep-04-20 12:52PM  
Sep-03-20 07:00AM  
Aug-18-20 12:00PM  
Aug-11-20 08:48AM  
Aug-10-20 07:35PM  
Aug-06-20 12:30PM  
Aug-05-20 04:05PM  
Jul-01-20 09:16AM  
Jun-19-20 04:05PM  
Jun-16-20 10:38PM  
Jun-15-20 04:05PM  
Jun-04-20 07:01PM  
Jun-02-20 11:41AM  
Jun-01-20 01:15PM  
May-30-20 11:31AM  
May-29-20 07:05AM  
May-27-20 04:05PM  
May-12-20 08:50AM  
Apr-30-20 09:55AM  
Apr-29-20 02:30PM  
Apr-15-20 11:30AM  
Mar-31-20 04:05PM  
Mar-30-20 11:54AM  
Mar-27-20 04:40PM  
Mar-17-20 11:52AM  
Mar-16-20 05:25PM  
Mar-05-20 12:30PM  
Feb-26-20 12:00PM  
Feb-19-20 09:08AM  
Feb-13-20 08:05AM  
Feb-12-20 04:26PM  
Jan-28-20 11:14AM  
Jan-27-20 07:00AM  
Jan-06-20 07:00AM  
Dec-20-19 05:34PM  
Dec-12-19 11:30AM  
Dec-04-19 07:00AM  
Nov-26-19 07:00AM  
Nov-19-19 07:00AM  
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SANDELL SCOTT D10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:30 PM
Sonsini Peter W.10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:31 PM
MAKOWER JOSHUA10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:29 PM
Makhzoumi Mohamad10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:28 PM
BASKETT FOREST10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:26 PM
Florence Anthony A. Jr.10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:27 PM
Growth Equity Opportunities Fu10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:26 PM